Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group IND.202 -- A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma -- was activated on 28 June 2010.

http://www.ctg.queensu.ca/trials/ind/i202/202.html